IPHA vs VALN
Innate Pharma SA and Valneva SE, side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | IPHA | VALN |
|---|---|---|
| Revenue | €9.0M | €174.7M |
| Net income | €-49.2M | €-115.2M |
| Gross margin | · | 38.7% |
| Net margin | −546.1% | −66.0% |
| Return on equity | · | · |
| Diluted EPS | −€0.55 | −€0.68 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €-52.9M | €-57.3M |
| Equity | · | · |
| Net debt / equity | · | 0.65× |
| Current ratio | 1.27× | 2.38× |
| Revenue CAGR 5y | −33.6% | 9.6% |
| Profit CAGR 5y | · | · |
VALN bills 19.4× the revenue of IPHA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | IPHA | VALN |
|---|---|---|
| FY2025 | €9.0M | €174.7M |
| FY2024 | €20.1M | €169.6M |
| FY2023 | €61.6M | €153.7M |
| FY2022 | €57.7M | €361.3M |
| FY2021 | €24.7M | €348.1M |
| FY2020 | €69.8M | €110.3M |
| FY2019 | €85.4M | €126.2M |
Bottom line
| Fiscal year | IPHA | VALN |
|---|---|---|
| FY2025 | €-49.2M | €-115.2M |
| FY2024 | €-49.5M | €-12.2M |
| FY2023 | €-7.6M | €-101.4M |
| FY2022 | €-58.1M | €-143.3M |
| FY2021 | €-52.8M | €-73.4M |
| FY2020 | €-64.0M | €-64.4M |
| FY2019 | €-20.8M | €-811,000 |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −€165,654,000 | VALN |
| FY2024 | −€149,458,000 | VALN |
| FY2023 | −€92,072,000 | VALN |
| FY2022 | −€303,629,000 | VALN |
| FY2021 | −€323,383,000 | VALN |
| FY2020 | −€40,548,000 | VALN |
| FY2019 | −€40,747,000 | VALN |
VALN has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 9 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −480.2 pp | VALN |
| FY2024 | −238.6 pp | VALN |
| FY2023 | +53.7 pp | IPHA |
| FY2022 | −61.1 pp | VALN |
| FY2021 | −192.7 pp | VALN |
| FY2020 | −33.3 pp | VALN |
| FY2019 | −22.9 pp | VALN |
The higher net margin has changed hands between IPHA and VALN over this period.
7 of 9 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IPHA's net margin has been more volatile than VALN's over the 7 comparable fiscal years — 171.5 percentage points of standard deviation against 25.5.
7 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between IPHA and VALN over these 7 fiscal years — IPHA led in 1 and VALN in 6.
7 of 9 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
VALN's return on equity has been more volatile than IPHA's over the 3 comparable fiscal years — 23.6 percentage points of standard deviation against 12.7.
3 of 8 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between IPHA and VALN over these 3 fiscal years — IPHA led in 2 and VALN in 1.
3 of 8 comparable fiscal years — a year missing data on either side is not counted.